Glycaemic control is the key to diabetes management. Starch blockers play a unique and important role in different classes of antidiabetic drugs. Ace Therapeutics is a contract research organization providing integrated services for the early-stage development of antidiabetic drugs. We are committed to providing customized solutions to support the development of novel starch blockers. Our experience in antidiabetic drug development makes us an ideal partner for conducting studies such as screening, optimization, pharmacodynamic and safety studies of starch blockers.
Starch blockers are an important antidiabetic drug used primarily to lower postprandial blood glucose levels. α-glucosidase inhibitors are important starch blockers. They can be administered alone or in combination therapy with other antidiabetic drugs. These enzyme inhibitors do not directly affect insulin secretion or sensitivity, unlike other antidiabetic drugs. Instead, they work by delaying the digestion of sugars found in starchy foods by raising post-meal levels of GLP-1 and lowering HbA1c levels. α-glucosidase inhibitors like acarbose and migitol have shown good efficacy in type 2 diabetes mellitus. Thus, the discovery and development of novel starch blockers could offer promising prospects for innovation in diabetes.
Fig. 1 Schematic
depiction of the involvement of α-amylase in postprandial hyperglycemia linked with starch hydrolysis. (Kashtoh, H.;
et al., 2023)
Ace Therapeutics provides clients with comprehensive starch blocker development services through our expertise in diabetes modeling and drug development. We are committed to providing one-stop starch blocker screening, optimization, pharmacodynamic profiling, efficacy and safety assessment services to provide reliable preclinical data for your antidiabetic drug development program.
We utilize our high-throughput screening technology in combination with a comprehensive strategy, which includes in vitro testing and animal experiments, to help our clients rapidly identify promising starch blockers. Our advanced technology and customized strategies allow us to help our clients discover antidiabetic drug candidates that effectively inhibit α-amylase and have good pharmacological properties.
We adopt a systematic, multidimensional approach to optimizing the structure and activity of starch blocker candidate s with the objective of improving drug properties and minimizing adverse effects. Our optimization process is designed to enhance key parameters, including potency, selectivity, pharmacokinetics and safety.
We conducted a comprehensive assessment of the activity of starch blocker candidates using customized in vivo and in vitro efficacy assessment assays.
We analyze the absorption, distribution, metabolism, and excretion (ADME) characteristics of starch blocker candidates, determining key PK parameters such as plasma half-life and clearance. Our professional services can provide you with reliable data support in starch blocker development.
Our comprehensive non-GLP toxicological assessment services, safety pharmacology study services, and toxicokinetic study services can help you identify potential safety risks and make informed decisions in the early development of starch blockers.
Ace Therapeutics has a portfolio of methods consisting of cutting-edge experimental approaches. Our experts are ready to work with you at any time to provide comprehensive solutions for starch blocker development for diabetes. Please feel free to contact us for more details.
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.